Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

SCLC,Extensive Stage × pembrolizumab × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 226 Melanoma 121 Squamous Cell Carcinoma of Head and Neck 119 Parkinson Disease 4, Autosomal Dominant Lewy Body 104 Neoplasm Metastasis 87 Lung Neoplasms 84 Triple Negative Breast Neoplasms 83 Neoplasms 76 Breast Neoplasms 70 Carcinoma, Renal Cell 62 Colorectal Neoplasms 60 Head and Neck Neoplasms 49 Stomach Neoplasms 44 Urinary Bladder Neoplasms 40 Ovarian Neoplasms 40 Carcinoma, Transitional Cell 38 Endometrial Neoplasms 37 Pancreatic Neoplasms 34 Carcinoma, Hepatocellular 33 Uterine Cervical Neoplasms 31 Prostatic Neoplasms 26 Esophageal Neoplasms 25 Glioblastoma 23 Carcinoma, Squamous Cell 23 Carcinoma 22 Brain Neoplasms 20 Skin Neoplasms 19 Sarcoma 19 Recurrence 19 Hodgkin Disease 19

Interventions

Etoposide 2 pembrolizumab 1 olaparib 1 niraparib 1 atezolizumab 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05623319 2025-06-24

THOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting

SCLC,Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon ⚡